S&P 500
$5,802.82
-0.7%
-$39.19
DJI
$41,603.07
-0.6%
-$256.02
NASDAQ
$18,737.21
-1.0%
-$188.53
Bitcoin
107,612.00
-0.1%
-69.03
AAPL
$195.55
-2.9%
-$5.81
AMZN
$201.33
-0.9%
-$1.77
GOOG
$169.68
-1.3%
-$2.30
META
$627.70
-1.4%
-$8.87
MSFT
$451.11
-0.8%
-$3.75
NVDA
$131.48
-1.0%
-$1.36
TSLA
$339.93
-0.3%
-$1.11
Alex Carchidi
TMFacarchidi
Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing.
Recent Articles by Alex Carchidi

Jan 18, 2025
by Alex Carchidi
Is Novo Nordisk Stock a Buy?

Jan 17, 2025
by Alex Carchidi
Is Recursion Pharmaceuticals Stock a Buy?

Dec 26, 2024
by Alex Carchidi
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?

Dec 23, 2024
by Alex Carchidi
Is AbbVie Stock a Buy?

Dec 22, 2024
by Alex Carchidi
Is Merck the Next Big Weight-Loss Stock?

Dec 20, 2024
by Alex Carchidi
1 Big New Green Flag for CRISPR Therapeutics' Stock

Dec 16, 2024
by Alex Carchidi
Is Teladoc Health Stock a Buy?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.